ALPHAMAB ONCOLOGY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.77 HKD | -0.83% |
|
-1.84% | -27.86% |
| 05-02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
| 04-10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALPHAMAB ONCOLOGY | Other Biotechnology & Medical Research | -0.83% | -1.84% | -27.86% | -39.97% | - | 577M |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- 9966 Stock
- Charts Alphamab Oncology
- Comparison Chart
